Japan Approves Minjuvi for Lymphoma Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- New Treatment Approval: Japan's Ministry of Health, Labour and Welfare has approved Minjuvi® (tafasitamab) in combination with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), providing a new option for patients, particularly those ineligible for autologous stem cell transplant.
- Clinical Trial Results: The L-MIND trial demonstrated an overall response rate of 58.8% for Minjuvi combined with lenalidomide, with a complete response rate of 41.3% and a partial response rate of 17.5%, while the J-MIND trial reported an even higher response rate of 71.4%, indicating the efficacy of this combination.
- Safety Assessment: Although the main adverse events included neutropenia and thrombocytopenia, the overall safety profile of Minjuvi in combination with lenalidomide was manageable, suggesting its clinical applicability.
- Market Outlook: This approval marks the second regulatory endorsement for Minjuvi in Japan, highlighting Incyte's commitment to addressing critical unmet needs and is expected to drive further growth in the Japanese market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to rise
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 98.990
Low
73.00
Averages
100.31
High
125.00
Current: 98.990
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of therapeutics. The Company operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise is comprised of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. The Company manages business activities on a consolidated basis through the development and commercialization of oncology and dermatology products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Japan Approves Minjuvi for Lymphoma Treatment
- New Treatment Approval: Japan's Ministry of Health, Labour and Welfare has approved Minjuvi® (tafasitamab) in combination with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), providing a new option for patients, particularly those ineligible for autologous stem cell transplant.
- Clinical Trial Results: The L-MIND trial demonstrated an overall response rate of 58.8% for Minjuvi combined with lenalidomide, with a complete response rate of 41.3% and a partial response rate of 17.5%, while the J-MIND trial reported an even higher response rate of 71.4%, indicating the efficacy of this combination.
- Safety Assessment: Although the main adverse events included neutropenia and thrombocytopenia, the overall safety profile of Minjuvi in combination with lenalidomide was manageable, suggesting its clinical applicability.
- Market Outlook: This approval marks the second regulatory endorsement for Minjuvi in Japan, highlighting Incyte's commitment to addressing critical unmet needs and is expected to drive further growth in the Japanese market.
See More
Incyte's Minjuvi Approved in Japan for DLBCL Treatment
- Drug Approval: Incyte Biosciences announced that Japan's Ministry of Health, Labour and Welfare has approved Minjuvi (tafasitamab) in combination with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), providing new treatment options for patients.
- Clinical Trial Support: This approval is supported by data from the global Phase II L-MIND study and Japan's Phase Ib/II J-MIND trial, which demonstrated strong response rates and durable clinical benefits in patients ineligible for autologous stem cell transplant.
- Safety Profile: The combination therapy maintained a manageable safety profile, with common side effects including neutropenia and thrombocytopenia, indicating its acceptability in treatment regimens.
- Market Impact: This marks Minjuvi's second approval in Japan, following its earlier authorization for relapsed or refractory follicular lymphoma, thereby expanding treatment options for this aggressive blood cancer.
See More
Zacks Premium Empowers Investors with Confidence and Insights
- Investor Confidence Boost: Zacks Premium offers daily updates on Zacks Rank and Industry Rank, aiding investors in making more informed decisions, thereby enhancing investment confidence and optimizing portfolios.
- Style Scoring System: The Zacks Style Scores rate stocks from A to F based on value, growth, and momentum characteristics, helping investors identify stocks with the potential to outperform the market over the next 30 days, thus enhancing the scientific approach to investing.
- Strong Earnings Outlook: Incyte Corporation (INCY) holds a Zacks Rank of #3 and a VGM Score of A, with a 0.8% increase in share price over the past four weeks, indicating its momentum appeal in the medical sector, attracting more investor attention.
- Expert Stock Recommendations: Five Zacks experts have each selected a stock expected to rise over 100% in the coming months, further boosting investor confidence in potential high-return stocks, especially in the current market environment.
See More
Mirum and Incyte Report Positive Results for FOP Study
- Clinical Trial Results: Mirum and Incyte's Phase II PROGRESS study of zilurgisertib showed that only 3.1% of patients developed new lesions compared to 16.7% in the placebo group, achieving an 81% reduction, indicating the drug's potential in treating this ultra-rare disease.
- Sustained Efficacy: In the open-label extension phase, no new lesions were observed among patients continuing zilurgisertib treatment at 48 weeks, with total lesion volume continuing to decline, demonstrating the drug's long-term efficacy and safety, addressing the urgent need for effective treatments.
- FDA Priority Review: Following positive clinical data, the FDA has accepted the NDA for zilurgisertib and granted Priority Review status, with a decision expected by September 26, 2026, which will expedite the drug's market entry to meet the demand for new therapies.
- Market Performance: Year-to-date, shares of Mirum and Incyte have risen by 28.5% and 1%, respectively, against a 1.4% decline in the biotech sector, reflecting investor optimism regarding their clinical advancements and enhancing their competitive position in the market.
See More
Mirum and Incyte Report Positive Phase 2 Data for Zilurgisertib
- Clinical Trial Results: Mirum Pharmaceuticals and Incyte have reported positive pivotal Phase 2 data for their oral FOP candidate, zilurgisertib, with results from Cohort 1 of the PROGRESS study showing consistent treatment effects on disease activity and durability through Week 48, indicating the drug's therapeutic potential.
- Safety Assessment: During the open-label extension, no new HO lesions were observed in patients continuing zilurgisertib treatment or in placebo patients who crossed over to active treatment at week 24, demonstrating the drug's safety and efficacy in long-term use.
- FDA Review Progress: The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application for zilurgisertib and granted Priority Review, with a target action date set for September 26, 2026, laying the groundwork for the drug's market launch.
- Market Outlook: Incyte's Chief Medical Officer Steven Stein stated that the findings represent an important milestone for the zilurgisertib program, further strengthening the clinical evidence supporting its potential as a treatment for FOP, signaling future market opportunities in the rare disease sector.
See More
Mirum and Incyte Announce New Progress in FOP Treatment
- Clinical Trial Results: At the ENDO 2026 conference, Mirum and Incyte presented results from Cohort 1 of the PROGRESS study, showing an 81% reduction in new heterotopic ossification lesions in patients treated with zilurgisertib, indicating significant efficacy in treating FOP.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for zilurgisertib and granted Priority Review, with a decision expected by September 26, 2026, which could provide urgently needed treatment options for FOP patients and potentially reshape the market landscape.
- Patient Data Analysis: During the 24-week double-blind period, patients receiving zilurgisertib had significantly fewer new lesions compared to the placebo group, and no new lesions were observed during the 48-week open-label extension, demonstrating sustained treatment effects and enhancing the drug's market potential.
- Safety Assessment: The study indicated that zilurgisertib was well-tolerated during the 24-week controlled period, with most adverse events being mild or moderate and no treatment discontinuations, paving the way for future commercialization and boosting investor confidence.
See More
Japan Approves Minjuvi for Lymphoma Treatment
- New Treatment Approval: Japan's Ministry of Health, Labour and Welfare has approved Minjuvi® (tafasitamab) in combination with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), providing a new option for patients, particularly those ineligible for autologous stem cell transplant.
- Clinical Trial Results: The L-MIND trial demonstrated an overall response rate of 58.8% for Minjuvi combined with lenalidomide, with a complete response rate of 41.3% and a partial response rate of 17.5%, while the J-MIND trial reported an even higher response rate of 71.4%, indicating the efficacy of this combination.
- Safety Assessment: Although the main adverse events included neutropenia and thrombocytopenia, the overall safety profile of Minjuvi in combination with lenalidomide was manageable, suggesting its clinical applicability.
- Market Outlook: This approval marks the second regulatory endorsement for Minjuvi in Japan, highlighting Incyte's commitment to addressing critical unmet needs and is expected to drive further growth in the Japanese market.
See More
Incyte's Minjuvi Approved in Japan for DLBCL Treatment
- Drug Approval: Incyte Biosciences announced that Japan's Ministry of Health, Labour and Welfare has approved Minjuvi (tafasitamab) in combination with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), providing new treatment options for patients.
- Clinical Trial Support: This approval is supported by data from the global Phase II L-MIND study and Japan's Phase Ib/II J-MIND trial, which demonstrated strong response rates and durable clinical benefits in patients ineligible for autologous stem cell transplant.
- Safety Profile: The combination therapy maintained a manageable safety profile, with common side effects including neutropenia and thrombocytopenia, indicating its acceptability in treatment regimens.
- Market Impact: This marks Minjuvi's second approval in Japan, following its earlier authorization for relapsed or refractory follicular lymphoma, thereby expanding treatment options for this aggressive blood cancer.
See More
Zacks Premium Empowers Investors with Confidence and Insights
- Investor Confidence Boost: Zacks Premium offers daily updates on Zacks Rank and Industry Rank, aiding investors in making more informed decisions, thereby enhancing investment confidence and optimizing portfolios.
- Style Scoring System: The Zacks Style Scores rate stocks from A to F based on value, growth, and momentum characteristics, helping investors identify stocks with the potential to outperform the market over the next 30 days, thus enhancing the scientific approach to investing.
- Strong Earnings Outlook: Incyte Corporation (INCY) holds a Zacks Rank of #3 and a VGM Score of A, with a 0.8% increase in share price over the past four weeks, indicating its momentum appeal in the medical sector, attracting more investor attention.
- Expert Stock Recommendations: Five Zacks experts have each selected a stock expected to rise over 100% in the coming months, further boosting investor confidence in potential high-return stocks, especially in the current market environment.
See More
Mirum and Incyte Report Positive Results for FOP Study
- Clinical Trial Results: Mirum and Incyte's Phase II PROGRESS study of zilurgisertib showed that only 3.1% of patients developed new lesions compared to 16.7% in the placebo group, achieving an 81% reduction, indicating the drug's potential in treating this ultra-rare disease.
- Sustained Efficacy: In the open-label extension phase, no new lesions were observed among patients continuing zilurgisertib treatment at 48 weeks, with total lesion volume continuing to decline, demonstrating the drug's long-term efficacy and safety, addressing the urgent need for effective treatments.
- FDA Priority Review: Following positive clinical data, the FDA has accepted the NDA for zilurgisertib and granted Priority Review status, with a decision expected by September 26, 2026, which will expedite the drug's market entry to meet the demand for new therapies.
- Market Performance: Year-to-date, shares of Mirum and Incyte have risen by 28.5% and 1%, respectively, against a 1.4% decline in the biotech sector, reflecting investor optimism regarding their clinical advancements and enhancing their competitive position in the market.
See More
Mirum and Incyte Report Positive Phase 2 Data for Zilurgisertib
- Clinical Trial Results: Mirum Pharmaceuticals and Incyte have reported positive pivotal Phase 2 data for their oral FOP candidate, zilurgisertib, with results from Cohort 1 of the PROGRESS study showing consistent treatment effects on disease activity and durability through Week 48, indicating the drug's therapeutic potential.
- Safety Assessment: During the open-label extension, no new HO lesions were observed in patients continuing zilurgisertib treatment or in placebo patients who crossed over to active treatment at week 24, demonstrating the drug's safety and efficacy in long-term use.
- FDA Review Progress: The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application for zilurgisertib and granted Priority Review, with a target action date set for September 26, 2026, laying the groundwork for the drug's market launch.
- Market Outlook: Incyte's Chief Medical Officer Steven Stein stated that the findings represent an important milestone for the zilurgisertib program, further strengthening the clinical evidence supporting its potential as a treatment for FOP, signaling future market opportunities in the rare disease sector.
See More
Mirum and Incyte Announce New Progress in FOP Treatment
- Clinical Trial Results: At the ENDO 2026 conference, Mirum and Incyte presented results from Cohort 1 of the PROGRESS study, showing an 81% reduction in new heterotopic ossification lesions in patients treated with zilurgisertib, indicating significant efficacy in treating FOP.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for zilurgisertib and granted Priority Review, with a decision expected by September 26, 2026, which could provide urgently needed treatment options for FOP patients and potentially reshape the market landscape.
- Patient Data Analysis: During the 24-week double-blind period, patients receiving zilurgisertib had significantly fewer new lesions compared to the placebo group, and no new lesions were observed during the 48-week open-label extension, demonstrating sustained treatment effects and enhancing the drug's market potential.
- Safety Assessment: The study indicated that zilurgisertib was well-tolerated during the 24-week controlled period, with most adverse events being mild or moderate and no treatment discontinuations, paving the way for future commercialization and boosting investor confidence.
See More
